Références :
Benson AB 3nd et al.
American Society of Clinical Oncology recommandations on adjuvant
chemotherapy for stage II colon cancer.
J
Clin Oncol 2004; 22: 3408-19.
International
Multicenter Pooled Analysis of B2 Colon Cancer
Trials (IMPACT B2) investigators- Efficacy of adjuvant Fluorouracil
and folinic Acid in B2 colon Cancer.
J
Clin Oncol 1999; 17: 1356-63.
Figueredo A et al.
Adjuvant therapy for stage II colon cancer : a systematic
review from the cancer care Ontario program in evidence-based
care's gastrointestinal cancer disease site group.
J
Clin Oncol 2004; 22 : 3395-407.
De Gramont A, et al.
Oxaliplatin/5FU/LV in adjuvant colon cancer : updated efficacy results of the MOSAIC trial, including survival, with a median follow up of six years.
J
Clin Oncol 2007; 25(18S) : 4007A
QUASAR Collaborative group
Adjuvant chemotherapy versus observation in patients with colorectal cancer : a randomised study.
Lancet 2007; 370 : 2020-29
Ribic CM, et al.
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
N Engl J Med 2003; 349: 247-57
Sargent DJ, et al.
Confirmation of deficient mismatch repair (dMMR) as apredictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (cc) : a pooled molecular reanalyses of randomized chemotherapy trials.
J Clin Oncol 2008; 26(S) = 4008A
|